A Magnetic Drug Delivery Capsule Based on a Coil Actuation Mechanism by Beccani, M et al.
 Procedia Engineering  120 ( 2015 )  53 – 56 
Available online at www.sciencedirect.com
1877-7058 © 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer-review under responsibility of the organizing committee of EUROSENSORS 2015
doi: 10.1016/j.proeng.2015.08.564 
ScienceDirect
EUROSENSORS 2015 
A magnetic drug delivery capsule based on a coil actuation mechanism 
Marco Beccani a, *, Christian Di Natali a, Gregorio Aiello a, b, Claire Benjamin a,              
Ekawahyu Susilo a, Pietro Valdastri a    
a STORM Lab, Department of Mechanical Engineering, Vanderbilt University, Nashville, TN 37212, USA. 
                                b Department of Biomedical Engineering, Politecnico di Milano, Piazza Leonardo da Vinci 20133 Milano, Italy. 
Abstract 
Current Wireless Capsule Endoscopic systems (WCE) provide only diagnostic tools, but in the future, advanced functionalities 
such as controllable drug delivery could be available for clinicians. This work introduces a Magnetic Drug Delivery Capsule 
(MDDC). The MDCC is based on a coil actuation mechanism that enables the deployment of a drug chamber from the device 
body. In this work, we present the prototype design and the results of bench trials that demonstrated the device ability to trigger 
the drug deployment by characterizing the magnetic field and resulting force. 
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1. Introduction   
Existing Wireless Capsule Endoscopic (WCE) systems are used to diagnose diseases in the Gastrointestinal (GI) 
tract. They embed a camera, a battery, and electronic circuits that allow physicians to collect pictures of the GI tract 
while they move through it.  Unfortunately, this technology has not yet been developed to the point where 
clinicians are able to perform an accurate therapeutic treatment.   However, there is the clinical need to target and 
treat specific pathologies, such as Crohn’s disease, obscure gastrointestinal bleeding (OGIB), and small intestinal 
tumors. Controllable drug delivery systems would enable the release of a specific amount of a given drug at an 
exact place in the GI tract. Hence, endeavors have been made by researchers [1-6] to perform regional drug 
absorption and to deliver a medication to a specific region of the GI tract such as the jejunum, ileum, ascending 
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colon, or descending colon through the progressive release of medication.  In this work, we present a Magnetic 
Drug Delivery Capsule (MDDC) for use in the release of common drugs in a solid form in the small bowel. The 
MDDC has a delivery mechanism based on magnetic attraction controlled by the current flow through an 
embedded copper coil. The MDDC consists of a cylindrical body in which the electronics and the batteries are 
embedded. At the top of this cylinder, the copper coil and a magnet are held, along with a separate drug chamber 
with the matching magnets. While the attraction between the magnets remains, the drug chamber maintains its 
connection to the body of the capsule. When the magnets repel one another, because of the force produced by the 
coil, the chamber is pushed outwards, allowing the delivery of the drug from the chamber to the target area of the 
GI tract. The MDDC does not require a motor for actuation and can hold extra sensors to enable real-time 
localization, thus ensuring an accurate on-site drug release [6].  
2. PRINCIPLE OF OPERATION 
Referring to Figure 1(a), the approach we propose for the MDDC takes advantage of two separate parts magnetically 
coupled: the capsule body and the drug chamber. In particular, while the capsule body embeds all the electronics 
modules, battery source and the drug releasing mechanism, the drug chamber can host up to 2.4 ml of drug. In order 
to prevent the drug from being delivered, four pairs of permanent axially magnetized NdFeB N-42 magnets (height 
= 2 mm, diameter = 1 mm, D101-N52, K&J Magnetics, US) are mounted to hold the drug chamber together with the 
body. The couples of magnets are mounted with a distance d of 4 mm between each other, resulting in the magnetic 
attractive force FM. We can express the attractive force FM as a function of the distance d, with Equation 1, (8):  
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where R and t are respectively the magnet radius and thickness, ?? is the magnetic permeability of space and M is 
the magnetization of the magnet, and n the number of magnets. The distance d was chosen such that, when a drug 
release is triggered, as shown in Figure 1(b), the current, IC, flowing through the coil generates the force FC, enough 
to cancel out the attractive force FM.  We can express the force F resulting on the system, neglecting the x and y 
components with Equation 2: 
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The resulting force F is negative only when the inter-magnetic force FM   is acting on the system and becomes 
positive when the coil is activated.  
 
 
Fig. 1: (a) The capsule body and the drug chamber hold together by the force FM. (b) The coil is remotely activated and greater than FM, triggers 
the release of the drug chamber. 
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A schematic view of the MDDC prototype is presented in Figure 2 with its main components. It has a cylindrical 
shape (13 mm in diameter, 30 mm in length, 12 g total mass). The cylindrical plastic shell and the drug chamber 
have been fabricated by rapid prototyping (OBJET 30, Objet Geometries Ltd, USA). The shell holds the embedded 
electronic circuit, a rechargeable battery, and the release mechanism. The embedded electronics consist of a flexible 
circuit [8] which hosts a microprocessor (MSP430, Texas Instruments, USA), a 433 MHz radio transceiver 
(CC1101, Texas Instruments, USA), a MOSFET to drive the coil (AO3442, Alpha Omega Semiconductor, China), 
and a LiPo rechargeable battery. The coil (ID 4.95 mm, OD 13.85 mm, h = 9.40 mm) has been manually wound and 
it consists of a copper insulated wire (d= 0.2 mm, Rtot = 8.6 ± 0.05 Ω, 695 loops), such coil was designed in order to 
provide a force Fc strong enough to decouple the magnets once activated (Fc > Fm). Figure 3 shows a picture of the 
final prototype with all the components, the lateral connectors are used only for the programming stage, they are cut 
away before folding the capsule. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: A schematic view of the MDCC prototype. 
  
 
 
 
 
 
Fig. 3: The MDCC prototype assembled before being folded into the shell. 
3.  Experimental Assessment 
The MDCC mechanism was characterized on bench with the platform shown in Figure 4(a).  The platform consists 
of a six Degree of Freedom (DoF) robotic manipulator (RV6SDL, Mitsubishi Corp., Japan) and an aluminum piece 
holding the drug chamber with the robot end effector. The rest of the release mechanism (the coil and the embedded 
electronics) was fixed to the manipulator table. To characterize the mechanism performance, a magnetic probe 
(KOSHAVA 5, Wuntronic, Germany) and a 6-DoF load cell (NANO17, ATI Industrial Automation, USA) were 
mounted to measure the resulting magnetic field and attractive/repelling force respectively, the drug deploying 
mechanism was triggered with current impulses of 580 mA±10 mA with a voltage of 3.3 V and a duration of 4s.  
Figure 5 (a) and Figure 5 (b) show respectively the resulting magnetic field and force on the system for one of the 
trials. The magnetic field, when the mechanism is not activated, is equal to -8 mT ± 0.25 mT, and reaches a value of 
+0.5 mT ± 0.25 mT when the coil is activated. As the plot shows, the magnetic field generated by the embedded 
magnets is canceled when the coil is activated, and the force increases from -12.6 mN ± 0.4 mN (attractive) to +4.55 
mN ± 0.52 mN. The attractive force results in a relative error of 4 % of what expressed by Equation 1.   The trial 
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showed how the coil was able to generate a magnetic field sufficient to cancel the magnetic coupling between the 
capsule body and the drug chamber, and thus, to release the drug by separating the two parts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: (a) The experimental platform to characterize the MDCC. (b) Measurements of the resulting magnetic field B, and force F (c).  
4. Conclusions and future works 
In this work we presented the MDCC, a device that can be wirelessly triggered to deploy a drug in the GI tract. We 
presented the design of the MDCC prototype, and then we characterized the force necessary to deploy the drug 
along with the resulting magnets and coil interaction magnetic field. Bench testing showed how the embedded 
fabricated coil enables the two parts to detach from one another. In the future, magnetic localization [7] can be 
integrated into the device to trigger drug deployment in the desired spot as well as to manipulate the capsule in the 
GI tract [9], and anchor the device to release all the drug by the same spot. Future works will aim to reduce the 
device size and to control the quantity of the drug released.  
Acknowledgements 
This work was supported by the National Science Foundation under Grant No. CNS-1239355 and No. IIS-1453129. 
Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and 
do not necessarily reflect the views of the National Science Foundation. 
References 
[1] I. Wilding, P. Hirst, A. Connor, (2000) Development of a new engineering- based capsule for human drug absorption studies, Pharma. Sci. 
Technol. Today, 3, 385–392. 
[2] F. Munoz, G. Alici, W. Li, (2014) A review of drug delivery systems for capsule endoscopy. Adv Drug Deliv Rev, 71, 77-85. 
[3] P. Xitian, L. Yulin, W. Kang, L. Hongying, W. Gang, Z. Xiaolin, W. Zhiyu, L. Deyu, (2010) A novel micro-fabricated thruster for drug 
release in remote controlled capsule, Sensors Actuators A Phys, 159, 227–232. 
[4] S. Yim, M. Sitti, (2012) Shape-programmable soft capsule robots for semi-implantable drug delivery, IEEE Trans Robotics, 28, 1198–1202. 
[5] S. P. Woods, T. G. Constandinou, (2013) Wireless capsule endoscope for targeted drug delivery: mechanics and design considerations, IEEE 
Trans Biomed Eng, 60, 945-953. 
[6] D. Vokoun, M. Beleggia, L. Heller, P. Sittner, (2009), Magnetostatic interactions and forces between cylindrical permanent magnets, Journal 
of Magnetism and Magnetic Materials, 321, 3758-3763.  
[7] C. Di Natali, M. Beccani, P. Valdastri, (2013) Real-time pose detection for magnetic medical devices, IEEE Trans Magn, 49, 3524-3527. 
[8] A. Taddese, M. Beccani, E. Susilo, P. Volgyesi, A. Ledeczi, and P. Valdastri, (2015), Toward rapid prototyping of miniature capsule robots 
IEEE International Conference on Robotics and Automation, ICRA 2015, 4704-4709.  
[9] G. Ciuti, P. Valdastri, A. Menciassi. P. Dario, (2010), Robotic magnetic steering and locomotion of capsule endoscope for diagnostic and 
surgical endoluminal procedures, Robotica, 28, 199-207. 
(a) 
(c) 
(b)
z
y
x
